THE USE OF CONCOMITANT STRONG CYP3A4 INDUCERS EG, DEXAMETHASONE, PHENYTOIN, CARBAMAZEPINE, RIFAMPIN, RIFABUTIN, PHENOBARBITAL MAY DECREASE DASATINIB PLASMA CONCENTRATIONS AND SHOULD BE AVOIDED. ST. JOHN'S WORT MAY DECREASE DASATINIB PLASMA CONCENTRATIONS UNPREDICTABLY AND SHOULD BE AVOIDED. IF PATIENTS MUST BE COADMINISTERED A STRONG CYP3A4 INDUCER, DASATINIB DOSE INCREASE SHOULD BE CONSIDERED.
CYP3A4 INHIBITORS EG, KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN, ATAZANAVIR, INDINAVIR, NEFAZODONE, NELFINAVIR, RITONAVIR, SAQUINAVIR, TELITHROMYCIN, AND VORICONAZOLE MAY INCREASE DASATINIB PLASMA CONCENTRATIONS. GRAPEFRUIT JUICE MAY ALSO INCREASE PLASMA CONCENTRATIONS OF DASATINIB AND SHOULD BE AVOIDED.
IF SPRYCEL MUST BE ADMINISTERED WITH A STRONG CYP3A4 INHIBITOR, A DOSE DECREASE SHOULD BE CONSIDERED. A DOSE DECREASE TO 20 MG DAILY SHOULD BE CONSIDERED FOR PATIENTS TAKING DASATINIB 100 MG DAILY & FOR PATIENTS TAKING 140 MG DAILY, A DOSE DECREASE TO 40 MG DAILY SHOULD BE CONSIDERED.